PRÉNUMBRA

Welcome to the Brand page for “PRÉNUMBRA”, which is offered here for Pharmaceuticals for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceuticals; pharmaceutical drugs for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical drugs; pharmaceutical preparations for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the treatment of vascular anomalies and oedema and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical preparations; pharmaceuticals used for cerebrovascular accidents in the nature of strokes; cardiovascular drug preparations; cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; cardiovascular medicinal agents for medical purposes; cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (chf); pharmaceutical preparations, preferably based on analogues of melanocyte stimulating hormone (msh), in particular afamelanotide for use in treating skin and skin relating conditions and disorders; medicated sun tanning preparations for pharmaceutical purposes, preferably based on analogues of melanocyte stimulating hormone (msh), in particular afamelanotide; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; medicated dermatological preparations; dermatological pharmaceutical substances; dermatological pharmaceutical products, preparations for treating or preventing skin disorders; medicinal creams for the protection of the skin; medicated skin care creams for medical use for treating or preventing skin disorders; medicated skin care preparations for medical use; medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; chemical and biological preparations, substances, reagents and compounds for the delivery and storage of a wide range of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (msh), in particular afamelanotide; afamelanotide hormone in aqueous and gel formulations;.

Its status is currently believed to be active. Its class is unavailable. “PRÉNUMBRA” is believed to be currently owned by “Clinuvel (UK) Ltd”.